[{"address1": "490 Arsenal Way", "address2": "Suite120", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "617 231 0700", "website": "https://www.c4therapeutics.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.", "fullTimeEmployees": 145, "companyOfficers": [{"maxAge": 1, "name": "Mr. Andrew J. Hirsch M.B.A.", "age": 52, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 986078, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Kenneth C. Anderson M.D., Ph.D.", "age": 72, "title": "Co-Founder, Independent Director & Member of Scientific Advisory Board", "yearBorn": 1951, "fiscalYear": 2023, "totalPay": 45000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stewart  Fisher Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 674572, "exercisedValue": 0, "unexercisedValue": 181975}, {"maxAge": 1, "name": "Dr. Leonard M. J. Reyno M.D.", "age": 61, "title": "Chief Medical Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1040820, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nathanael S. Gray Ph.D.", "title": "Co-Founder & Member of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kendra  Adams", "title": "CFO & Treasurer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Mossler", "age": 50, "title": "Chief Accounting Officer", "yearBorn": 1973, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jolie M. Siegel J.D.", "age": 46, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1977, "fiscalYear": 2023, "totalPay": 610400, "exercisedValue": 1063000, "unexercisedValue": 1335958}, {"maxAge": 1, "name": "Ms. Kelly A. Schick", "age": 43, "title": "Chief People Officer", "yearBorn": 1980, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Isabel  Chiu Ph.D.", "title": "Senior Vice President of Strategic Alliances & Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 2, "boardRisk": 6, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 5.87, "open": 5.9, "dayLow": 5.655, "dayHigh": 6.04, "regularMarketPreviousClose": 5.87, "regularMarketOpen": 5.9, "regularMarketDayLow": 5.655, "regularMarketDayHigh": 6.04, "beta": 3.062, "forwardPE": -3.554878, "volume": 1140242, "regularMarketVolume": 1140242, "averageVolume": 1560164, "averageVolume10days": 1001570, "averageDailyVolume10Day": 1001570, "bid": 5.77, "ask": 5.87, "bidSize": 100, "askSize": 100, "marketCap": 404239360, "fiftyTwoWeekLow": 1.06, "fiftyTwoWeekHigh": 11.88, "priceToSalesTrailing12Months": 13.759934, "fiftyDayAverage": 5.855, "twoHundredDayAverage": 6.05275, "currency": "USD", "enterpriseValue": 211331616, "floatShares": 45791345, "sharesOutstanding": 69337800, "sharesShort": 10503384, "sharesShortPriorMonth": 11625527, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.1515, "heldPercentInsiders": 0.11649, "heldPercentInstitutions": 0.88443, "shortRatio": 7.64, "shortPercentOfFloat": 0.1842, "bookValue": 3.59, "priceToBook": 1.6239555, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -107868000, "trailingEps": -1.9, "forwardEps": -1.64, "pegRatio": -0.19, "enterpriseToRevenue": 7.194, "enterpriseToEbitda": -1.843, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CCCC", "underlyingSymbol": "CCCC", "shortName": "C4 Therapeutics, Inc.", "longName": "C4 Therapeutics, Inc.", "firstTradeDateEpochUtc": 1601645400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b41c1949-bef0-3b7c-8399-8d0a5d83bcc2", "gmtOffSetMilliseconds": -14400000, "currentPrice": 5.83, "targetHighPrice": 39.0, "targetLowPrice": 8.0, "targetMeanPrice": 16.0, "targetMedianPrice": 14.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 264098000, "totalCashPerShare": 3.809, "ebitda": -114686000, "totalDebt": 68417000, "quickRatio": 4.894, "currentRatio": 5.093, "totalRevenue": 29378000, "debtToEquity": 27.693, "revenuePerShare": 0.494, "returnOnAssets": -0.19253, "returnOnEquity": -0.44873002, "freeCashflow": -33949248, "operatingCashflow": -77808000, "revenueGrowth": 3.507, "grossMargins": -2.57492, "operatingMargins": -1.7859399, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]